Merck & Co., Inc. (MRK), Zoetis Inc (ZTS), Kellogg Company (K) – Shorts Are Piling Into These Stocks. Should You Be Worried?

Page 1 of 2

The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term. But when you look at individual stocks, you’ll find plenty that lose money over the long haul. According to hedge fund institution Blackstar Funds, even with dividends included, between 1983 and 2006, 64% of stocks underperformed the Russell 3000, a broad-scope market index.

A large influx of short-sellers shouldn’t be a condemning factor to any company, but it could be a red flag from traders that something may not be as cut-and-dried as it appears. Let’s look at three companies that have seen a rapid increase in the number of shares sold short and see whether traders are blowing smoke or if their worry has some merit.

Company Short Increase May 15 to May 31 Short Shares as a % of Float
Merck & Co., Inc. (NYSE:MRK) 303.2% 3.1%
Zoetis Inc (NYSE:ZTS) 1,037.2% 19.2%
Kellogg Company (NYSE:K) 118.2% 2.7%

Source: The Wall Street Journal.

An ailing pipeline? Hardly!
For a big pharmaceutical company like Merck & Co., Inc. (NYSE:MRK) that pays out a hefty 3.6% yield and demonstrates very low volatility (its beta is just 0.37), it’s a bit surprising to see its short interest more than quadrupling.

Merck & Co., Inc. (NYSE:MRK)

About the only factor I can think of that would cause such pessimism among investors is the potential that patent expirations will ravage Merck’s cash flow before new drugs can be approved or purchased to replace this lost revenue. For Merck & Co., Inc. (NYSE:MRK), these fears manifested themselves in the loss of exclusivity of asthma drug Singulair last year, which had topped $5 billion in annual sales at its peak. In its most recent quarter, Singulair sales fell by 75%.

However, plenty of very-early-stage and new drug approvals could prove short-sellers wrong about Merck & Co., Inc. (NYSE:MRK)’s pipeline. In May, Liptruzet, an LDL-cholesterol-lowering drug that combines Pfizer Inc. (NYSE:PFE)‘s now generic statin, Lipitor, with Merck’s cholesterol absorption inhibitor, Zetia, was approved by the Food and Drug Administration. The combo drug did far better in lowering LDL cholesterol (the bad type) than the two drugs did individually.

Another bright spot was the recently completed American Society of Clinical Oncology’s annual meeting. Merck & Co., Inc. (NYSE:MRK) wasn’t expected by many to make a strong showing, but wowed investors with its experimental PD-1 inhibitor, lambrolizumab. Most investors and science enthusiasts had their eyes on Bristol Myers Squibb Co. (NYSE:BMY)‘s nivolumab, which demonstrated an overall response rate of 40% in trials. But it was lambrolizumab, with its overall response rate of 38%, that excited investors — especially since it has the “breakthrough therapy” designation from the FDA, which would help streamline its development. Anti-PD-1 drugs could be the future of targeted cancer therapy, so both Bristol and Merck deserve close attention.

Paws off, short-sellers!
Perhaps as equally confusing as the dramatic rise in short interest in Merck is the jump in pessimism surrounding animal medicine and vaccine maker Zoetis Inc (NYSE:ZTS).

The best picture I can surmise that would cast doubt over Zoetis Inc (NYSE:ZTS) is the upcoming spinoff of Pfizer Inc. (NYSE:PFE)’s remaining 80% stake. Current Pfizer shareholders have the opportunity, if they choose, to tender their shares in exchange for shares of Zoetis. Depending on the number of shareholders who take part in this tender, Pfizer could retain no stake in Zoetis, a partial stake, or it could still boast a majority voting stake. To me it would be more advantageous for Zoetis to be able to run its business independently of Pfizer Inc. (NYSE:PFE), so this slight gray cloud of worry could be the short-selling culprit.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!